Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in San Donato Milanese – page 159

2 835 clinical trials in San Donato Milanese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
San Donato Milanese at a glance
2 835
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 835 trials in San Donato Milanese

Open in trial search

Gastric cancer+2

Not recruiting

Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Arcus Biosciences Inc.

Mantle cell lymphoma

Not recruiting

Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Italiana Linfomi Ets

Partial seizures

Not recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

K-ras gene mutation+3

Not recruiting

Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:Novartis Pharma AG

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Anaemia+1

Not recruiting

Study on KER-050 and Ruxolitinib for Patients with Myelofibrosis and Anemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Takeda Development Center Americas Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Hepatitis B virus test+1

Not recruiting

Study on the Effects of Selgantolimod and NUC Discontinuation in Patients with Chronic Hepatitis B

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Entecavir
  • Sponsor:ANRS Maladies Infectieuses Emergentes

Transitional cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of MK-2870, Enfortumab Vedotin, and Pembrolizumab for Patients with Advanced Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Gastrointestinal stromal tumour

Not recruiting

Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ripretinib
  • Sponsor:Deciphera Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in San Donato Milanese

What the registry says about research in the country

01 Gastroenterology Research

Leading studies focusing on inflammatory bowel diseases, including investigations of novel treatments for Crohn's Disease and Ulcerative Colitis. Research encompasses both established and experimental therapies aimed at inducing clinical remission.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatments
  • Fecal Incontinence Therapy

Multiple trials evaluating innovative therapeutic approaches for gastrointestinal conditions.

02 Cardiovascular Studies

Comprehensive research into heart conditions, with particular emphasis on hypertrophic cardiomyopathy and heart failure. Studies evaluate new medications and surgical interventions.

  • Heart Failure Management
  • Cardiac Surgery Outcomes
  • Myocardial Infarction Research

Innovative approaches in treating various cardiac conditions using precision medicine techniques.

03 Immunology Research

Groundbreaking studies in hereditary angioedema and chronic urticaria, investigating both preventive treatments and acute attack management strategies.

  • Hereditary Angioedema Treatments
  • Chronic Urticaria Management
  • Pediatric Immunology Studies

Advanced therapeutic options being developed for rare immunological disorders.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.